This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioPharm America
2 days in-person. 2 days virtually.
September 28–29, 2022 | Boston, USAOctober 4–5, 2022 | Virtual



Progeneer is a research-led biotechnology company located in South Korea with expertise in nanotechnology. As our name Progeneer indicates, we are pioneers in protein and gene focused on engineering life for the better. We harness nucleic acids engineering to express protein in a cell free environment and envision a new paradigm for manufacturing biotherapeutics. Our vaccine adjuvant platform employs lipid nanotechnology and will be the solution to better protecting the world against diseases. Together, these technologies will empower next generation therapeutics tailored to a single patient. Progeneer was founded in 2019 and currently has ~35 employees working on various technology platforms. The three main pillars of research are cell free protein synthesis (CFPS), individualized vaccine, and vaccine adjuvant. Progeneer’s CFPS is a groundbreaking technology that can be implemented in protein providing services or high-volume manufacturing of biotherapeutics.